J

Johnson & Johnson

Makes prescription drugs and medical devices

Psr

Full-TimeUpdated
No salary listed
Mid
Bachelor's, Master's
Hefei, Anhui, China
In PersonField-based role; some travel is required.
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree or higher is required; a bachelor's degree in medicine, pharmacy, clinical practice, imaging, or ultrasound is preferred, and a master's degree in cardiac electrophysiology is preferred.
  • Ability to perform the job duties independently and pass relevant professional knowledge examinations.
  • Sales experience in the pharmaceutical or medical industry is preferred.
  • Professional medical English proficiency is preferred.
  • Use professional electrophysiology knowledge and skills to support operators during procedures and ensure they are safe and proceed smoothly.
  • Become familiar with customers' procedural practices, communicate effectively with operators, continuously improve professional skills, and independently support arrhythmia procedures ranging from simple to complex within the assigned region.
  • Keep up with industry and company developments; proactively learn new concepts, technologies, products, advantages, and use cases; and develop targeted, actionable promotional communication plans.
  • Use new products, digital tools, and technologies proficiently, and assist the professional education team in improving operators' understanding, skills, and confidence.
  • Effectively communicate the value of new products and technologies and increase customer acceptance so procedures can be performed safely and efficiently for patients.
  • Create challenging and executable sales plans based on regional conditions; improve professional selling skills and competitive sales capability; and achieve sales targets.
  • Visit professional customers, deepen customer understanding and insight, identify customer needs, provide high-quality solutions based on market changes and current business developments, and maintain effective working relationships.
  • Accelerate new-product market access and address market-access risks to support a favorable non-clinical and policy environment for business development.
  • Build effective relationships with distributors and periodically train them on products, technology, processes, and compliance.
  • Be willing to travel to develop peripheral markets and bring products and technology to more hospitals and patients.
  • Comply strictly with company policies and complete other duties assigned by the manager.
  • Demonstrate self-motivation, strong execution, responsiveness, collaboration, resilience, and innovative problem-solving.
Responsibilities
  • Provide procedural support to operators using professional electrophysiology knowledge and skills, ensuring procedures are safe and proceed smoothly.
  • Independently support simple-to-complex arrhythmia procedures across the assigned region, adapting to customer procedural practices and communicating with operators.
  • Learn and promote new concepts, technologies, and products, and develop targeted promotional communication plans.
  • Use new products, digital tools, and technologies and support professional education for operators.
  • Communicate the value of new products and technologies and improve customer acceptance.
  • Develop and execute regional sales plans and achieve sales targets.
  • Visit customers, assess needs, provide tailored solutions, and maintain effective customer relationships.
  • Accelerate new-product access and address market-access risks.
  • Build distributor relationships and deliver periodic product, technology, process, and compliance training.
  • Travel to develop peripheral markets and serve more hospitals and patients.
  • Comply with company policies and perform other duties assigned by the manager.
Desired Qualifications
  • A bachelor's degree in medicine, pharmacy, clinical practice, imaging, or ultrasound is preferred.
  • A master's degree in cardiac electrophysiology is preferred.
  • Sales experience in the pharmaceutical or medical industry is preferred.
  • Professional medical English proficiency is preferred.

About the company

J

Johnson & Johnson

View
Website

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

7%

1 year growth

-1%

2 year growth

-1%
Associated Press
Oct 27th, 2026
Pomerantz investigates Johnson & Johnson after 5.73% share drop on talc charges and MedTech miss

Pomerantz LLP is investigating whether Johnson & Johnson (J&J) and some of its officers or directors engaged in securities fraud or other unlawful business practices. The law firm advises affected investors to contact Danielle Peyton at [email protected]. On October 13, 2026, J&J reported third-quarter GAAP net earnings of $210 million, or $0.09 per share. Multi-billion dollar special charges tied to its talc litigation settlement weighed on the result. Its MedTech segment grew only 2.5% to $8.64 billion, a second straight revenue miss. J&J cited pricing constraints in China and disruption in the Middle East. The stock fell $15.12, or 5.73%, to close at $248.61 that day.

Yahoo Finance
Oct 27th, 2026
J&J sees $34.7M net ETF outflow, extending selling streak to four days

ETFs sold a net $34.7 million of Johnson & Johnson stock on Friday, October 23, extending a four-day run of net selling. SPY led the move, cutting $34.6 million, or 0.44% of its stake. XLV sold $24.6 million and DIA $6.3 million. More funds bought than sold, with 26 ETFs adding shares and 17 cutting them, but their purchases were smaller. Net outflows were $55.2 million on October 22, $54.1 million on October 21, and $19.8 million on October 20. A net inflow of $38.1 million came on October 19. Johnson & Johnson has a market cap of $641.1 billion. It reported $99.35 billion in trailing-12-month revenue, up 7.0% over one year.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.